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A B S T R A C T
Differences in the glucose metabolism were examined and analysed in this study between patients treated with olan-
zapine and risperidone in comparison with healthy volunteers. The aim of the study was to determine differences of the
impaired glucose metabolism in the study groups as well as to point out to the possible mechanisms which bring to these
differences. To the group of 15 schizophrenic patients treated with olanzapine, and group of 15 schizophrenic patients
treated with risperidone and to 14 healthy volunteers oral glucose tolerancy test is applied in order to determine the level
of the impaired glucose tolerance. In the group of the patients treated with olanzapine glucose tolerance was impaired in
33% of the patients, while in the group of the patients treated with risperidone in 20%. Impaired glucose tolerance mostly
manifested as hyperinsulinemia. Authors discussed about possible mechanisms responsible for the impaired glucose tol-
erance in the patients treated with new antipsychotics. Authors conclude that insulin resistance is the main mechanism
for development of the diabetes type II in the schizophrenic patients treated with antipsychotics. Insulin resistance is the
result of the multiple effects of the antipsychotics, among which most common are: increased body mass and direct in-
volvement of the antipsychotics in the glucose metabolism.
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Introduction
Second generation antipsychotics, compared with
first generation antipsychotics, brought significant ad-
vantages in the treatment of the patients suffering from
schizophrenia and schizophrenia like diseases. Their big-
gest advantage is better tolerance because of the weaker
manifested and rarer extrapiramidal side effects. But,
some of the second generation antipsychotics induce in-
creased body mass, induce risk of development of diabe-
tes type II and risk of dyslipidemia and therefore in-
crease prevalence of metabolic syndrome in the popu-
lation of schizophrenic patients. Contribution of second
generation antipsychotics to increased body mass, to the
impaired glucose metabolism and dyslipidemia in the pa-
tients with schizophrenia is not easy to asses because of
the other factors that influence the development of these
disorders (family history, sitting lifestyle, inadequate eat-
ing habits, smoking, physical illnesses, abuse of the psy-
choactive substances, social disfunctionality…). Never-
theless, higher prevalence of diabetes in the schizophre-
nic population was described even before the develop-
ment of the antipsychotics. That implies the idea that the
impaired glucose metabolism in the schizophrenic pa-
tients could be connected with the nature of the disease.
Introduction of the chlorpromazin in the therapy of the
schizophrenia brought to the higher body mass, diabetes
type II and dyslipidemia. But with second generation
antipsychotics these metabolic disorders get into con-
cerning proportions. Today the prevalence of diabetes
among schizophrenic patients is twice higher than in the
general population. Connection of these metabolic dis-
turbances and some of the second generation antipsy-
chotics is confirmed on the many levels: through case re-
ports, retrospective studies and strictly controlled
clinical trials. Therefore there is no doubt that some
antipsychotics, especially second generation antipsycho-
tics, apply to this twice as high prevalence of diabetes
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type II among schizophrenic patients compared with
general population1–5. A lot of facts show that the risk of
diabetes in schizophrenic patients has significantly grown
after the inclusion of second generation antipsychotics in
the therapy6–8. Although there are informations about
development of diabetes type II with almost every anti-
psychotic9–12, higher risk for development of diabetes
type II and diabetic kethoacidosis is especially related
with dibenzodiazepines – olanzapine and clozapine13–16.
Potential mechanisms of the development of antipsy-
chotic induced diabetes type II are multiple, but the most
relevant risk factor is considered to be antipsychotics’ in-
duced higher body mass with increase of insulin resisten-
cy17. Increased body mass antipsychotics cause by block-
ing certain receptors which mediate in the control of the
satiety. Therefore, some antipsychotics block histami-
nergic H1 receptors, whose stimulation is connected with
reduction of the food intake. Furthermore, antipsycho-
tics which block 5-HT2C receptors also through hipo-
thalamus produce higher appetite and food intake in the
body. Also, many antipsychotics block adrenergic recep-
tors (a1,a2, b) which play significant role in the control
of the appetite and in the controll of the glucose metabo-
lism1,18–20. Controlled trials suggests that dibenzodiaze-
pines (clozapine and olanzapine) might directly influence
the insulin resistance and glucose tolerance, independ-
ently of body mass. It is assumed that in that case
hyperglycemia develops because of the 5-HT1A receptors
blocking at the b cells of the pancreas. 5-HT2A receptors
may also be included in the glucose metabolism control.
But the precise role of these receptors in the regulation
of the glucose metabolism is not fully known. Probably,
different antipsychotics produce hiperglycemia in differ-
ent possible multiple ways. In that way can be explained
their different power in the provocation of diabetes. For
example, with olanzapine is connected 37% higher risk of
development of diabetes compared with risperidone21.
Higher risk of diabetes with olanzapine compared with
risperidone may be connected with increased body mass,
as well as with the direct affect of olanzapine to the glu-
cose metabolism. Besides, for the development of the dia-
betes type II can be responsible the possibility of some
antipsychotics to block the glucose transport in the pe-
ripheral tissues by blocking the influence of the insulin
on the transport proteins1,18.
Subjects and Methods
Study was conducted on the 44 subjects: 30 patients
with schizophrenia, diagnosed according to the DSM IV
criteria, and 14 healthy volunteers. Patients with schizo-
phrenia were included by random choice. Inclusion crite-
ria were: signed informed consent for the study, age from
18–65, at least one prior episode of schizophrenia accord-
ing to the DSM-IV criteria – for the group of patients, for
at least 6 months continuous therapy with risperidone or
olanzapine. In the trial were not included patients with
diabetes or with the information of diabetes in their rela-
tives. Fifteen of the patients treated with olanzapine and
fifteen with risperidone. There were no significant differ-
ences in the length of the treatment with investigated
antipsychotic between the two groups. All of the patients
were treated with the first generation antipsychotics in
the prior episode. Routine measurement of the body
weight gave us the insight in the body weight of the pa-
tients at the beginning of the treatment with risperidone
or olanzapine. Group of healthy volunteers and groups of
patients did not significantly differ according to the body
weight and body mass index, although in the time of
measurement the patients treated with olanzapine were
the most heavier in the average. Oral glucose tolerancy
test (OGTT-test according to the WHO recommenda-
tions) were applied to the all subjects. At the defined time
points (0, 60, 120, 180 min) blood samples were taken for
the measurement of the glucose concentrations (enzime
measurements with hexokinases, Olympus); insulin
(ELIZA, Mercadone) and C-peptide (ELIZA, Mercadone)
in the serum. Referent ranges for laboratory values after
fasting were: glucose = 4.2–6.4 mmol/L; insulin = 2–25
mU/L; C-peptide 343–1803 pmol/L. Criteria for the im-
paired glucose tolerance were: fasting serum concentra-
tions of glucose ³6.5 mmol/L, serum concentration of glu-
cose in oral glucose tolerance test (75 grams) after 120
min ³8.0 mmol/L; fasting serum concentration of insulin
³26 mU/L, serum concentration of insulin in oral glucose
tolerance test ³100 mU/L. The results were analysed de-
scriptively and with Exact Mann-Whitney U test for du-
ration of therapy; Kruskal-Wallis test for age, body mass,
BMI, glucose, insulin and C-peptide.
Results
According to the set criteria glucose tolerancy was im-
paired in 3 patients receiving risperidone (20%) and 5 pa-
tients receiving olanzapine (33%). In the group of healthy
volunteers there were no impairement of the glucose
tolerancy. A fasting hyperglycemia (7.2 mmol/L) is found
in one patient receiving olanzapine. Impaired glucose
tolerancy had in total 8 patients (23%). In the OGTT- test
average glucose concentration in the group receiving
olanzapine were higher than in the group of healthy vol-
unteers in the 120 minute. Significant differences were
found in the insulin concentrations in OGTT test be-
tween the group receiving olanzapine and the group of
healthy volunteers in the 60., 120. and 180. minute as
well as between the group receiving olanzapine and the
group receiving risperidone in the 0. and 60. minute.
Changes in the concentrations of C-peptide as expected
followed changes in the insulin concentrations, which
confirms endogen etiology of the insulin. (Table 1, Figure
1, Figure 2)
Discussion
The results of this study point out the significant
number of patients with impaired glucose tolerance in
the group of patients treated with olanzapine as well as
in the group of patients receiving risperidone. The re-
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sults are in concordance with the previous studies which
compared risk from diabetes melitus type II in the pa-
tients treated with olanzapine, risperidone and conven-
tional antipsychotics. According to these studies, higher
risk of diabetes was among the patients treated with
olanzapine. Higher risk, but in the lower degree exists
also in the patients treated with risperidone and with
first generation antipsychotics5,18,19. In this study, the re-
sults which have already published in the short ver-
sion20, there are also differences observed in the preva-
lence of impaired glucose metabolism between the pa-
tients receiving olanzapine and those receiving risperi-
done. This difference was not noticed in the fasting glu-
cose measurements but in the OGTT test, and the most
impressive pointer of the impaired glucose tolerance was
hyperinsulinemia. Precise mechanisms in which anti-
psychotics cause hyperglycemia still remains unclear.
Mostly mentioned are: increased body weight, increased
body mass index (BMI), with insulin resistance after-
wards21,22, blockade of the serotoninergic 5 HT1A recep-
tors on the b cells of the pancreas independently of the
body mass14 and pancreatitis caused with antipsycho-
tics23,24. It seems that body weight and accompanied in-
sulin resistance play important role in the increased risk
for diabetes type II patients treated with atypical anti-
psychotics. This hypothesis also supports higher com-
pensatory secretion of insulin and C-peptide in the pa-
tients without diabetes with atypical antipsychotic the-
rapy during the oral glucose tolerance test, as in the
study by Yazicki25. In this study all of three measured pa-
rameters during the oral glucose tolerance test (glucose
response and compensatory insulin and C-peptide secre-
tion) were significantly higher in the patients compared
with the healthy volunteers. Concentrations of glucose,
insulin and C-peptide were higher, but not significantly,
in the patients treated with olanzapine compared to
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TABLE 1
SERUM CONCENTRATIONS OF GLUCOSE, INSULIN AND C-PEPTIDE IN HEALTHY SUBJECTS (N=14), SCHIZOPHRENIC PATIENTS
TAKING RISPERIDONE (N=15) AND OLANZAPINE (N=15) IN ORAL GLUCOSE TOLERANCE TEST.
Healthy N=14 Risperidone N=15 Olanzapine N=15 p*
Male 5 6 5
Female 9 9 10
Age, median (25%–75%) 41.5 (37–44) 42 (37–53) 38 (31–42) 0.233
Duration of therapy (months),
median (25%–75%)
– 17 (14–19) 14 (13–28) 0.504
TT1 72 (59.75–87.5) 73 (63–88) 75 (71–84) 0.833
TT2 73 (63.75–85) 76 (65–91) 84 (76–92) 0.179
BMI, median (25%–75%)
BMI1 25.55 (21.45–29.425) 27.2 (21.8–29.6) 26.2 (25–27.1) 0.981
BMI2 25.7 (22.1–29.275) 27.9 (22.3–30.6) 28.0 (26.9–31.3) 0.182
Glucose, median (25%–75%)
Zero point 5.25 (4.975–6.05) 5.4 (5.1–5.6) 5.4 (5.1–5.8) 0.989
After 60 minutes 6.35 (5.4–7.05) 8 (5.8–10.8) 9 (6.7–11.8) 0.077
After 120 minutes 4.75 (4.175–5.775) 6.2 (5.1–7.5) 6.6 (5.2–8.6)† 0.027
After 180 minutes 4.5 (4.05–5.0) 5.2 (4.2–5.5) 4.5 (4.0–5.8) 0.196
Insulin, median (25%–75%)
Zero point 9.3 (7.7–11.4) 8.3 (5.7–9.5) 13.2 (9.3–19.2)‡ 0.008
After 60 minutes 46.7 (28.35–75.25) 52.9 (36–83.9) 102.6 (62.6–117.0)†‡ 0.014
After 120 minutes 11.75 (9.075–36.5) 32 (20.0–54.2) 51.6 (36.4–72.1)† 0.001
After 180 minutes 7.5 (2.95–8.8) 19.2 (5.4–39.6) 16 (10.7–33.9)† 0.002
C–peptide, median (25%–75%)
Zero point 389.5 (109.5–1179.25) 462 (315–733) 566 (435–742) 0.278
After 60 minutes 1908 (986.5–3097.25) 2002 (1686–2765) 2865 (1509–3820) 0.171
After 120 minutes 1406 (376.75–2338.5) 1752 (1513–3447) 3222 (2320–3920)†‡ 0.001
After 180 minutes 365.5 (115.5–1128.25) 1250 (358–2354) 2057 (1280–2371)†‡ 0.001
* Exact Mann-Whitney U test for duration of therapy; Kruskal-Wallis test for age, body mass, BMI, glucose, insulin and C-peptide
† Significantly higher then in the healthy group (p<0.05; post-hoc exact Mann-Whitney U test with Bonferroni correction)
‡ Significantly higher then in the group of patients taking risperidone (p<0.05; post-hoc exact Mann-Whitney U test with Bonferroni
correction)
those treated with risperidone. BMI was higher in the
patients treated with olanzapine compared with the
healthy volunteers. In the group of patients treated with
risperidone there were no significant difference in the
BMI compared with the healthy volunteers. Therefore,
difference in the body weight can be one of the explana-
tions for the different results in the group of patients
treated with different medications. Because of the small
sample, study results hardly could distinguish direct in-
fluence of the antipsychotics to the impaired glucose tol-
erance from the direct impact through body weight gain,
so they should be taken with restrictions. One can only
speculate about the possible mechanisms responsible for
the development of the diabetes mellitus in the patients
receiving the antipsychotic therapy. However, since there
was not significant difference in the BMI between the pa-
tients treated with risperidone and the patients treated
with olanzapine, and there are significant differences in
the hyperinsulinemia between those two groups, it can
be assumed that for the higher hyperinsulinemia in the
olanzapine group with higher body weight obesity is the
one that might be responsible for direct influence of
olanzapine to the insulin resistance. It still remains the
question of the risk for diabetes type II during the treat-
ment with the second generation antipsychotics. First of
all this risk is not possible to asses on the basis the re-
sults of the fasting glucose concentrations in the serum.
This research and other researches’ results show that
the best pointer of the higher risk for diabetes in the pa-
tients receiving the antipsychotics is higher insulin resis-
tance. It can be best determined by the measurement of
the insulin concentration in the OGTT test. The patients
have higher insulin resistance as a sign of the overbur-
den system for the control of the glucose metabolism
years before the appearance of the diabetes26. Therefore
to the every patient subjected to the antipsychotic with a
higher risk for metabolic syndrome, OGTT test should be
done, including the insulin measurement, in order to
asses the risk for diabetes type II. OGTT test should be
also done in every significant change in the body weight27,
no matter which antipsychotic the patient is taking. Al-
though, other risk factors for development of the diabe-
tes type II can, even with low diabetes risk antipsy-
chotics, produce metabolic disturbances, as well as all of
the other elements of metabolic syndrome28–30.
Conclusion
Second generation antipsychotics affect the glucose
metabolism of the schizophrenic patients in the different
ways. In this study olanzapine has more often and stron-
ger impaired glucose metabolism compared with the
risperidone, although such impairments also existed in
the patients treated with risperidone. The best pointer of
the higher risk for diabetes in the patients treated with
antipsychotics is higher insulin resistance manifested in
the OGTT test with hyperinsulinemia. Therefore, to as-
sess the risk for the diabetes type II in the patients re-
ceiving antipsychotics, the measurement of the insulin
concentrations in the OGTT test should be included.
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Fig. 1. Serum concentrations of glucose in healthy subjects (N=
14), schizophrenic patients taking risperidone (N=15) and olan-





















Fig. 2. Serum concentrations of insulin in healthy subjects (N=
14), schizophrenic patients taking risperidone (N=15) in oral
glucosae tolerance test.
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DRUGA GENERACIJA ANTIPSIHOTIKA I RIZIK OD DIJABETESA TIPA II
– USPOREDBA IZME\U OLANZAPINA I RISPERIDONA
S A @ E T A K
U ~lanku su prikazani i analizirani rezultati ispitivanja razlike u metabolizmu glukoze izme|u bolesnika lije~enih
olanzapinom i risperidonom te zdravih ispitanika. Cilj ispitivanja bio je utvrditi razlike u o{te}enju metabolizma gluko-
ze u ispitivanim skupinama i ukazati na mogu}e mehanizme koji dovode do tih razlika. Na skupinama od 15 shizofrenih
bolesnika lije~enih olanzapinom, 15 shizofrenih bolesnika lije~enih risperidonom i 14 zdravih dragovoljaca primjenjen
je oralni test optere}enja glukozom (OGTT) u cilju procjene stupnja o{te}enosti tolerancije glukoze. U skupini na olan-
zapinu tolerancija glukoze bila je o{te}ena kod 33% bolesnika, a u skupini na risperidonu kod njih 20%. O{te}ena
tolerancija glukoze naj~e{}e se manifestirala hiperinzulinemijom. Autori raspravljaju o mogu}im mehanizima odogo-
vornim za o{te}enu toleranciju glukoze kod bolesnika koji uzimaju nove antipsihotike. Zaklju~uju da je inzulinska rezi-
stencija glavni mehanizam razvoja dijabetesa tip II u shizofrenih lije~enih antipsihoticima. Inzulinska rezistencija je
posljedica vi{estrukih u~inaka antipsihotika, me|u kojima su naj~e{}i: porast tjelesne te`ine i izravno uplitanje antipsi-
hotika u metabolizam glukoze.
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